在STAT3高IgE综合征中使用度普利尤单抗治疗后湿疹缓解及Th1极化恢复。 - Suppr

Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome.

作者信息

Matucci-Cerinic Caterina, Viglizzo Gianmaria, Pastorino Carlotta, Corcione Anna, Prigione Ignazia, Bocca Paola, Bustaffa Marta, Cecconi Massimiliano, Gattorno Marco, Volpi Stefano

机构信息

Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI), Università degli Studi di Genova, Genova, Italy.

Unità Operativa Semplice Dipartimentale Centro Malattie Autoinfiammatorie e Immunodeficienze, IRCCS Istituto Giannina Gaslini, Genova, Italy.

出版信息

Pediatr Allergy Immunol. 2022 Apr;33(4):e13770. doi: 10.1111/pai.13770.

DOI:10.1111/pai.13770

PMID:35470938

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9321118/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aee0/9321118/dc39d67e5a3f/PAI-33-0-g002.jpg

相似文献

Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome.

Pediatr Allergy Immunol. 2022 Apr;33(4):e13770. doi: 10.1111/pai.13770.

Dupilumab treatment of eczema in a child with STAT3 hyper-immunoglobulin E syndrome.

J Eur Acad Dermatol Venereol. 2022 May;36(5):e367-e369. doi: 10.1111/jdv.17889. Epub 2022 Jan 8.

Relieving job: Dupilumab in autosomal dominant STAT3 hyper-IgE syndrome.

J Allergy Clin Immunol Pract. 2022 Jan;10(1):349-351.e1. doi: 10.1016/j.jaip.2021.08.042. Epub 2021 Sep 16.

Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome.

Clin Immunol. 2020 Jun;215:108452. doi: 10.1016/j.clim.2020.108452. Epub 2020 Apr 29.

Dupilumab for STAT3-Hyper-IgE Syndrome With Refractory Intestinal Complication.

Pediatrics. 2021 Sep;148(3). doi: 10.1542/peds.2021-050351. Epub 2021 Aug 20.

Clinical Profile of Hyper-IgE Syndrome in India.

Front Immunol. 2021 Feb 26;12:626593. doi: 10.3389/fimmu.2021.626593. eCollection 2021.

Omalizumab in the Treatment of Hyper-IgE Syndrome: 2 Case Reports.

J Investig Allergol Clin Immunol. 2020;30(3):191-192. doi: 10.18176/jiaci.0469. Epub 2019 Dec 10.

Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab.

Pediatr Dermatol. 2022 Nov;39(6):940-942. doi: 10.1111/pde.15072. Epub 2022 Jun 22.

[Hyper-IgE syndromes].

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jun 5;31(11):892-896. doi: 10.13201/j.issn.1001-1781.2017.11.019.

Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern.

Allergy. 2014 Jul;69(7):943-53. doi: 10.1111/all.12416.

引用本文的文献

β-Actin Deficiency in Baraitser-Winter Syndrome Type 1 Disrupts T-Cell Function and Immune Regulation: Implications for Targeted Therapy in Actinopathies.

J Clin Immunol. 2025 Aug 1;45(1):120. doi: 10.1007/s10875-025-01906-x.

Dual biological treatments in immune-mediated disorders: a single center experience.

BMC Immunol. 2025 Apr 8;26(1):29. doi: 10.1186/s12865-025-00705-8.

The genetics of hyper IgE syndromes.

Front Immunol. 2025 Feb 18;16:1516068. doi: 10.3389/fimmu.2025.1516068. eCollection 2025.

Inborn errors of immunity with atopic phenotypes in the allergy and immunology clinic: a practical review.

Curr Opin Allergy Clin Immunol. 2025 Apr 1;25(2):105-114. doi: 10.1097/ACI.0000000000001059. Epub 2025 Feb 13.

Infections in Inborn Errors of STATs.

Pathogens. 2024 Nov 1;13(11):955. doi: 10.3390/pathogens13110955.

Improvement in Atopic Dermatitis and Recurrent Infection With Dupilumab in Children With Distinct Genetic Types of Hyper-IgE Syndrome: A Case Series and Literature Review.

Pediatr Dermatol. 2025 Mar-Apr;42(2):376-382. doi: 10.1111/pde.15780. Epub 2024 Oct 18.

Monogenic Inborn Errors of Immunity with impaired IgG response to polysaccharide antigens but normal IgG levels and normal IgG response to protein antigens.

Front Pediatr. 2024 Jun 12;12:1386959. doi: 10.3389/fped.2024.1386959. eCollection 2024.

The treatment efficacy of dupilumab in autosomal dominant hyper-immunoglobulin E syndrome with severe atopic dermatitis.

Asia Pac Allergy. 2024 Mar;14(1):39-41. doi: 10.5415/apallergy.0000000000000121. Epub 2023 Oct 9.

Management of Atopy with Dupilumab and Omalizumab in CADINS Disease.

J Clin Immunol. 2024 Jan 17;44(2):48. doi: 10.1007/s10875-023-01636-y.

ERBIN and phosphoglucomutase 3 deficiency.

Curr Opin Immunol. 2023 Oct;84:102353. doi: 10.1016/j.coi.2023.102353. Epub 2023 Jun 25.

本文引用的文献

Relieving job: Dupilumab in autosomal dominant STAT3 hyper-IgE syndrome.

J Allergy Clin Immunol Pract. 2022 Jan;10(1):349-351.e1. doi: 10.1016/j.jaip.2021.08.042. Epub 2021 Sep 16.

Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome.

J Allergy Clin Immunol Pract. 2021 Nov;9(11):4167-4169. doi: 10.1016/j.jaip.2021.06.049. Epub 2021 Jul 16.

Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis.

JAAD Case Rep. 2021 Mar 9;11:60-62. doi: 10.1016/j.jdcr.2021.03.007. eCollection 2021 May.

Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome.

Clin Immunol. 2020 Jun;215:108452. doi: 10.1016/j.clim.2020.108452. Epub 2020 Apr 29.

IL-4 enhances IL-10 production in Th1 cells: implications for Th1 and Th2 regulation.

Sci Rep. 2017 Sep 12;7(1):11315. doi: 10.1038/s41598-017-11803-y.

IL-4 impairs wound healing potential in the skin by repressing fibronectin expression.

J Allergy Clin Immunol. 2017 Jan;139(1):142-151.e5. doi: 10.1016/j.jaci.2016.07.012. Epub 2016 Aug 20.

Sensitivity and resistance to regulation by IL-4 during Th17 maturation.

J Immunol. 2011 Nov 1;187(9):4440-50. doi: 10.4049/jimmunol.1002860. Epub 2011 Sep 26.

STAT3 is required for IL-21-induced secretion of IgE from human naive B cells.

Blood. 2008 Sep 1;112(5):1784-93. doi: 10.1182/blood-2008-02-142745. Epub 2008 Jun 25.

Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome.

Nature. 2008 Apr 10;452(7188):773-6. doi: 10.1038/nature06764. Epub 2008 Mar 12.

STAT3 mutations in the hyper-IgE syndrome.

N Engl J Med. 2007 Oct 18;357(16):1608-19. doi: 10.1056/NEJMoa073687. Epub 2007 Sep 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome.

Pediatr Allergy Immunol. 2022 Apr;33(4):e13770. doi: 10.1111/pai.13770.

Dupilumab treatment of eczema in a child with STAT3 hyper-immunoglobulin E syndrome.

J Eur Acad Dermatol Venereol. 2022 May;36(5):e367-e369. doi: 10.1111/jdv.17889. Epub 2022 Jan 8.

Relieving job: Dupilumab in autosomal dominant STAT3 hyper-IgE syndrome.

J Allergy Clin Immunol Pract. 2022 Jan;10(1):349-351.e1. doi: 10.1016/j.jaip.2021.08.042. Epub 2021 Sep 16.

Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome.

Clin Immunol. 2020 Jun;215:108452. doi: 10.1016/j.clim.2020.108452. Epub 2020 Apr 29.

Dupilumab for STAT3-Hyper-IgE Syndrome With Refractory Intestinal Complication.

Pediatrics. 2021 Sep;148(3). doi: 10.1542/peds.2021-050351. Epub 2021 Aug 20.

Clinical Profile of Hyper-IgE Syndrome in India.

Front Immunol. 2021 Feb 26;12:626593. doi: 10.3389/fimmu.2021.626593. eCollection 2021.

Omalizumab in the Treatment of Hyper-IgE Syndrome: 2 Case Reports.

J Investig Allergol Clin Immunol. 2020;30(3):191-192. doi: 10.18176/jiaci.0469. Epub 2019 Dec 10.

Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab.

Pediatr Dermatol. 2022 Nov;39(6):940-942. doi: 10.1111/pde.15072. Epub 2022 Jun 22.

[Hyper-IgE syndromes].

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jun 5;31(11):892-896. doi: 10.13201/j.issn.1001-1781.2017.11.019.

Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern.

Allergy. 2014 Jul;69(7):943-53. doi: 10.1111/all.12416.

引用本文的文献

β-Actin Deficiency in Baraitser-Winter Syndrome Type 1 Disrupts T-Cell Function and Immune Regulation: Implications for Targeted Therapy in Actinopathies.

J Clin Immunol. 2025 Aug 1;45(1):120. doi: 10.1007/s10875-025-01906-x.

Dual biological treatments in immune-mediated disorders: a single center experience.

BMC Immunol. 2025 Apr 8;26(1):29. doi: 10.1186/s12865-025-00705-8.

The genetics of hyper IgE syndromes.

Front Immunol. 2025 Feb 18;16:1516068. doi: 10.3389/fimmu.2025.1516068. eCollection 2025.

Inborn errors of immunity with atopic phenotypes in the allergy and immunology clinic: a practical review.

Curr Opin Allergy Clin Immunol. 2025 Apr 1;25(2):105-114. doi: 10.1097/ACI.0000000000001059. Epub 2025 Feb 13.

Infections in Inborn Errors of STATs.

Pathogens. 2024 Nov 1;13(11):955. doi: 10.3390/pathogens13110955.

Improvement in Atopic Dermatitis and Recurrent Infection With Dupilumab in Children With Distinct Genetic Types of Hyper-IgE Syndrome: A Case Series and Literature Review.

Pediatr Dermatol. 2025 Mar-Apr;42(2):376-382. doi: 10.1111/pde.15780. Epub 2024 Oct 18.

Monogenic Inborn Errors of Immunity with impaired IgG response to polysaccharide antigens but normal IgG levels and normal IgG response to protein antigens.

Front Pediatr. 2024 Jun 12;12:1386959. doi: 10.3389/fped.2024.1386959. eCollection 2024.

The treatment efficacy of dupilumab in autosomal dominant hyper-immunoglobulin E syndrome with severe atopic dermatitis.

Asia Pac Allergy. 2024 Mar;14(1):39-41. doi: 10.5415/apallergy.0000000000000121. Epub 2023 Oct 9.

Management of Atopy with Dupilumab and Omalizumab in CADINS Disease.

J Clin Immunol. 2024 Jan 17;44(2):48. doi: 10.1007/s10875-023-01636-y.

ERBIN and phosphoglucomutase 3 deficiency.

Curr Opin Immunol. 2023 Oct;84:102353. doi: 10.1016/j.coi.2023.102353. Epub 2023 Jun 25.

本文引用的文献

Relieving job: Dupilumab in autosomal dominant STAT3 hyper-IgE syndrome.

J Allergy Clin Immunol Pract. 2022 Jan;10(1):349-351.e1. doi: 10.1016/j.jaip.2021.08.042. Epub 2021 Sep 16.

Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome.

J Allergy Clin Immunol Pract. 2021 Nov;9(11):4167-4169. doi: 10.1016/j.jaip.2021.06.049. Epub 2021 Jul 16.

Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis.

JAAD Case Rep. 2021 Mar 9;11:60-62. doi: 10.1016/j.jdcr.2021.03.007. eCollection 2021 May.

Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome.

Clin Immunol. 2020 Jun;215:108452. doi: 10.1016/j.clim.2020.108452. Epub 2020 Apr 29.

IL-4 enhances IL-10 production in Th1 cells: implications for Th1 and Th2 regulation.

Sci Rep. 2017 Sep 12;7(1):11315. doi: 10.1038/s41598-017-11803-y.

IL-4 impairs wound healing potential in the skin by repressing fibronectin expression.

J Allergy Clin Immunol. 2017 Jan;139(1):142-151.e5. doi: 10.1016/j.jaci.2016.07.012. Epub 2016 Aug 20.

Sensitivity and resistance to regulation by IL-4 during Th17 maturation.

J Immunol. 2011 Nov 1;187(9):4440-50. doi: 10.4049/jimmunol.1002860. Epub 2011 Sep 26.

STAT3 is required for IL-21-induced secretion of IgE from human naive B cells.

Blood. 2008 Sep 1;112(5):1784-93. doi: 10.1182/blood-2008-02-142745. Epub 2008 Jun 25.

Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome.

Nature. 2008 Apr 10;452(7188):773-6. doi: 10.1038/nature06764. Epub 2008 Mar 12.

STAT3 mutations in the hyper-IgE syndrome.

N Engl J Med. 2007 Oct 18;357(16):1608-19. doi: 10.1056/NEJMoa073687. Epub 2007 Sep 19.

Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献